PKI - PerkinElmer, Inc.
Chart Events
Triple Moving Average Crossover
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 99.30 |
| Open | 99.90 |
| Bid | 98.60 x 1400 |
| Ask | 103.08 x 1100 |
| Day's Range | 98.67 - 100.58 |
| 52 Week Range | 62.91 - 102.46 |
| Volume | 805,277 |
| Avg. Volume | 1,025,771 |
| Market Cap | 11.191B |
| Beta (5Y Monthly) | 1.34 |
| PE Ratio (TTM) | 49.79 |
| EPS (TTM) | 2.02 |
| Earnings Date | Jul 27, 2020 - Jul 31, 2020 |
| Forward Dividend & Yield | 0.28 (0.28%) |
| Ex-Dividend Date | Jul 16, 2020 |
| 1y Target Est | 89.33 |
Fair Value
Related Research
- Business Wire
PerkinElmer to Present at Jefferies Global Healthcare Conference
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the (virtual) Jefferies Global Healthcare Conference on Thursday, June 4, 2020 at 9:00 a.m. ET.
- MarketWatch
PerkinElmer denies Reuters report that it is being investigated in a Medicare fraud case
PerkinElmer Inc. said Monday that it has not received any information, and is not aware of any wrongdoing, as implied by a Reuters report. The diagnostics and health services company also said it did not have any information that it or any of its personnel are being investigated by the government. The company's statement comes after Reuters reported, citing sources and documents reviewed by Reuters, that PerkinElmer faced a federal investigation into its role in an alleged Medicare fraud involving unnecessary genetic cancer tests. PerkinElmer acknowledged that it has received subpoenas, but they were regarding investigations into third parties. The company said it has fully cooperated with authorities. The stock rose 0.1% in morning trading. It has slipped 1.3% over the past three months, while the S&P 500 has lost 12.7%.
- Business Wire
Official Statement from PerkinElmer in Response to Reuters Article Published on May 18, 2020
PerkinElmer, Inc. (NYSE: PKI) supports government efforts to identify and prevent abusive practices in healthcare. PerkinElmer has received subpoenas from the government regarding investigations into third parties, and has fully cooperated with authorities and will continue to do so. The Company is not aware of, and has not received any information regarding, wrongdoing by PerkinElmer, as implied by Reuters, nor does PerkinElmer have any information that the Company or any of our personnel are the target of a government investigation.
- Reuters
Exclusive: U.S. probes PerkinElmer's role in massive Medicare fraud - sources
Medical diagnostic firm PerkinElmer Inc faces a federal investigation into its role in an alleged Medicare fraud involving tens of thousands of unnecessary genetic cancer tests, according to three sources with knowledge of the probe and documents reviewed by Reuters. The firm conducted the tests now under scrutiny over 18 months, earning millions of dollars, according to one of those sources and three others familiar with the company's lab operations. Investigators are probing whether Massachusetts-based PerkinElmer enabled a scheme by some its laboratory clients, two of which the government previously has charged in connection with alleged Medicare fraud, said the three sources with knowledge of the probe.
- Moody's
PerkinElmer, Inc. -- Moody's announces completion of a periodic review of ratings of PerkinElmer, Inc.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of PerkinElmer, Inc. New York, May 15, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of PerkinElmer, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
- Zacks
PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates
PerkinElmer's (PKI) first-quarter results benefit from growth in Discover & Analytics Solutions segment. However, forex remains a woe.
- MarketWatch
The FDA tightens rules around antibody tests as companies talk up their value
The Food and Drug Administration’s decision to crack down on a loose set of regulatory requirements for antibody tests follows concerns about test validity and fraud.
- Thomson Reuters StreetEvents
Edited Transcript of PKI earnings conference call or presentation 5-May-20 9:00pm GMT
Q1 2020 PerkinElmer Inc Earnings Call
- Motley Fool
PerkinElmer Inc (PKI) Q1 2020 Earnings Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Q1 2020 PerkinElmer Earnings Conference Call. With me on the call are Prahlad Singh, President and Chief Executive Officer; and Jamey Mock, Senior Vice President and Chief Financial Officer. Statements or comments made on this call may be forward-looking statements, which may include, but are not necessarily limited to, financial projections or other statements of the company's plans, objectives, expectations or intentions.
- Zacks
PerkinElmer (PKI) Q1 Earnings and Revenues Beat Estimates
PerkinElmer (PKI) delivered earnings and revenue surprises of 42.55% and 1.75%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
PerkinElmer Announces Financial Results for the First Quarter of 2020
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the first quarter ended April 5, 2020.
- Business Wire
FDA Provides Emergency Use Authorization to PerkinElmer for Serological Test to Identify COVID-19 Antibodies
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that the U.S. Food and Drug Administration (FDA) has provided Emergency Use Authorization (EUA) for EUROIMMUN’s (a PerkinElmer company) Anti-SARS-CoV-2 ELISA (IgG) serology test. Clinical laboratories certified to perform high complexity tests under Clinical Laboratory Improvement Amendments (CLIA) can immediately begin using this ELISA for the detection of antibodies of the immunoglobulin class G.
- Business Wire
PerkinElmer to Present at BofA Securities Virtual Healthcare Conference 2020
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the annual BofA Securities Virtual Healthcare Conference 2020 on Thursday, May 14, 2020 at 8:20 a.m. ET.
- Business Wire
PerkinElmer Board Declares Quarterly Dividend
The Board of Directors of PerkinElmer, Inc. (NYSE: PKI), declared a regular quarterly dividend of $0.07 per share of common stock on April 30, 2020. This dividend is payable on August 7, 2020 to all shareholders of record at the close of business on July 17, 2020.
- Zacks
Analysts Estimate PerkinElmer (PKI) to Report a Decline in Earnings: What to Look Out for
PerkinElmer (PKI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Do Its Financials Have Any Role To Play In Driving PerkinElmer, Inc.'s (NYSE:PKI) Stock Up Recently?
PerkinElmer (NYSE:PKI) has had a great run on the share market with its stock up by a significant 18% over the last...
- Business Wire
Notice of Change of Location of Annual Meeting of Shareholders of PerkinElmer to Be Held on April 28, 2020
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, gave notice today that in response to continued public health restrictions on in-person gatherings given the coronavirus/COVID-19 pandemic, the Board of Directors of PerkinElmer has determined to change the format of the company’s Annual Meeting of Shareholders scheduled for Tuesday, April 28, 2020, at 8:00 a.m. EST from in-person to virtual-only. The meeting will be webcast and can be accessed by stockholders at www.virtualshareholdermeeting.com/PKI2020 using the 16-digit control number on their proxy card, voting instruction form or Notice of Internet Availability. The company has designed the format of the Annual Meeting to ensure that shareholders are afforded the same rights and opportunities to participate as they would at an in-person meeting, using online tools to ensure shareholder access and participation. For additional information regarding accessing and participating in the virtual meeting, please refer to the company’s supplemental proxy materials filed with the Securities and Exchange Commission on April 14, 2020.
- Business Wire
PerkinElmer to Hold Earnings Call on Tuesday, May 5, 2020
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that on Tuesday, May 5, 2020, after market close, the Company will release first quarter 2020 results. The Company will also host a conference call the same day at 5:00 p.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Jamey Mock, senior vice president and chief financial officer, will host the conference call.
- PR Newswire
Beaumont Health launches the nation's largest serological testing study for COVID-19 antibodies
Beaumont Health's Research Institute is launching America's largest serological testing study to help answer many questions surrounding the spread of COVID-19 and potentially help treat patients battling the virus.
- Zacks
FDA EUA for Coronavirus Tests Boosts MedTech: 3 Stocks in Focus (Revised)
These key biotech and molecular diagnostic players banking on the receipt of FDA's EUA for COVID-19 tests are currently outperforming the broader industries they belong to.
- Zacks
FDA EUA for Coronavirus Tests Boosts MedTech: 3 Stocks in Focus
These key biotech and molecular diagnostic players banking on the receipt of FDA's EUA for COVID-19 tests are currently outperforming the broader industries they belong to.
- Zacks
Here's Why You Should Hold On to PerkinElmer (PKI) Stock Now
PerkinElmer (PKI) expects to witness foreign exchange headwinds in 2020.
- Zacks
PerkinElmer (PKI) Receives EUA for Coronavirus Detection Test
PerkinElmer (PKI) introduces test for the detection of coronavirus after it receives EUA for the same.
- MarketWatch
PerkinElmer gets emergency OK from FDA for coronavirus test
PerkinElmer Inc. said late Tuesday it received an emergency use authorization from the Food and Drug Administration so labs can start using its test for SARS-CoV-2, the virus that causes COVID-19. PerkinElmer shares rose 1% after hours, following a 9.5% rise to finish the regular session at $74.31. "Despite the challenging environment, our employees have demonstrated unwavering commitment over the past two months to combat this global pandemic," said Prahlad Singh, PerkinElmer president and chief executive, in a statement.
